NEW YORK--(BUSINESS WIRE)--Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.
As part of the transaction, Tom Oxley, Synchron’s CEO & Founder, will join the ACQUANDAS Governance Council and Riki Banerjee, Synchron’s CTO, will join as Observer.
“As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” said Oxley.
“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor. This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market,” said CEO & Founder Dr. Rodrigo Lima de Miranda, ACQUANDAS.
ACQUANDAS has established an entirely new generation of shape-memory, flexible metallic components suitable for use as medical devices. Their capability to manufacture miniaturized structures, such as micro-patterned Nitinol thin films, combined with high structure resolution and geometrical complexity, excellent biocompatibility and improved mechanical properties, provides Synchron with a unique product offering in the implantable medical device industry.
About Synchron
Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and autonomy for individuals with motor impairment. Synchron is headquartered in New York City. For more information, visit www.synchron.com. Follow us @synchroninc.
